publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
T-DXd
Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
Edoxaban
Direct oral anticoagulant dosing in patients with atrial fibrillation: An Asian perspective
T-DXd
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
Pexidartinib
Supporting patients in the transition to the revised pexidartinib dosing regimen: Perspectives from the multidisciplinary clinical and allied health professional team
HER3-DXd
Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: A multicenter, phase I/II trial
HER3-DXd
Current and emerging treatment options for patients with metastatic EGFR-mutated non-small cell lung cancer after progression on osimertinib and platinum-based chemotherapy: A podcast discussion
T-DXd
Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
HER3-DXd
EGFR mutations are not all the same: The importance of biomarker testing in non-small cell lung cancer (NSCLC)—a podcast discussion between patients and oncologists
Edoxaban
Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: The ETNA-AF-Europe registry
Valemetostat
Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects